UCB SA (OTCMKTS:UCBJY) Sees Large Growth in Short Interest

UCB SA (OTCMKTS:UCBJY) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,600 shares, an increase of 1,200.0% from the March 31st total of 200 shares. Based on an average trading volume of 24,200 shares, the days-to-cover ratio is presently 0.1 days.

UCB Stock Performance

Shares of OTCMKTS UCBJY traded down $0.10 during trading on Friday, reaching $66.48. The company had a trading volume of 36,784 shares, compared to its average volume of 12,573. UCB has a twelve month low of $34.85 and a twelve month high of $67.30. The stock has a 50-day moving average price of $59.68 and a two-hundred day moving average price of $48.03.

UCB Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 29th will be given a $0.4574 dividend. This represents a dividend yield of 0.71%. The ex-dividend date is Friday, April 26th. UCB’s dividend payout ratio is currently 46.55%.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.